Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 5, 2011, Pages 965-966

  Vallet, Hélène ^a   Houitte, Ronan ^a   Azria, Alexandre ^a   Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GANCICLOVIR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISONE; RITUXIMAB; VALGANCICLOVIR;

AGED; CASE REPORT; COLITIS; COLON BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G DEFICIENCY; LETTER; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGAMMAGLOBULINEMIA; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; OPPORTUNISTIC INFECTIONS; POLYMERASE CHAIN REACTION;

EID: 79955563176     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100818     Document Type: Letter

References (13)

1. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008;57:714-5. (Pubitemid 351579988)
2. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007;13:1365-8. (Pubitemid 350206846)
3. Papadakis KA, Rosenbloom B, Targan SR. Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's diesease. Gastroenterology 2003;124:583. (Pubitemid 36169274)
4. Wirtz N, Schader SI, Holtappels R, Simon CO, Lemmermann NAW, Reddehase MJ, et al. Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med Microbiol Immunol 2008;197:151-8.
5. Medlicott SA, Coderre S, Horne G, Panaccione R. Multimodal immunosuppressant therapy in steroid-refractory common variable immunodeficiency sprue: a case report complicating cytomegalovirus infection. Int J Surg Pathol 2006;14:101-6. (Pubitemid 43221627)
6. Wada Y, Sato T, Kitajima H, Kubo M. Chronic cytomegalovirus infection that present specific clinical course - a case of a boy with common variable immunodeficiency. Nihon Rinsho Meneki Gakkai Kaishi 1995;18:247-55.
7. Daniels JA, Ledermoan HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007;31:1800-12. (Pubitemid 350175807)
8. Sarmiento E, Fernandez-Yanez J, Munoz P, Palomo J, Rodriguez-Molina JJ, Bermejo J, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol 2005;5:97-101. (Pubitemid 39626690)
9. Kahraman A, Miller M, Maldonado-Lopez E, Baba HA, Treichel U, Gerken G. A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and cytomegalovirus infection [German]. Med Klin (Munich) 2009;104:150-4.
10. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908. (Pubitemid 350262316)
11. Van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clincial trials. J Rheumatol 2010;37:558-67.
12. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Hematol 2009;146:120-2.
13. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al; Autoimmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.